Singapore Association of Pharmaceutical Industries

We are delighted to announce Dr. Praful Chakkarwar, Country Manager for Novo Nordisk, as the newest member of our Board of Directors! With over 18 years of pharmaceutical experience spanning Turkey, India, Asia, Oceania, Latin America, and Africa, Dr. Chakkarwar brings a wealth of global expertise to SAPI.   As we welcome Dr. Chakkarwar, we also take this opportunity to thank Ms. Serene Chang, General Manager at Amgen, for her contributions and time on the Board.   We look forward to advancing SAPI’s key priorities with Dr. Chakkarwar’s leadership and contributions to the Board. Please join us in welcoming him as we continue shaping the future of SAPI together! 🎉

Our SAPI Patient Engagement and Partnering (PEP) team is proud to have collaborated with Sandpiper Health on a workshop to strengthen the communication skills of patient organizations.   In her opening remarks, PEP Lead Weeling Quek emphasized our commitment to fostering transparent, respectful partnerships that place patients at the heart of healthcare innovation and decision-making.   This workshop is part of SAPI’s ongoing efforts to empower and uplift patient organizations through meaningful engagement and capability building. If you’re interested in joining future sessions or exploring collaboration opportunities, we’d love to hear from you.   Thank you to all participants for your unwavering dedication to supporting patients and shaping better healthcare outcomes! Dr Aditi Sobti WeeKim YEO Winnie Tan (陈炜霓) Jet Lee Jonathan Teo Chen Penny Hwee Tee Poh Abdullahi Sheriff Christina Teo

Earlier this week, SAPI members had a unique opportunity to explore the role of Alternative Dispute Resolution (ADR) in addressing complex issues in life sciences, thanks to an exclusive event co-hosted with the World Intellectual Property Organization – WIPO and its WIPO Arbitration and Mediation Center. Our members heard directly from WIPO’s experts on how ADR can be effectively applied in the life sciences sector to address challenges such as licensing agreements, patent disputes, R&D collaborations, and more. A special thanks to our speakers: • Christina Teo, Executive Director of SAPI, who opened the session with a thoughtful introduction on the importance of ADR in supporting innovation. • Caleb Goh, Legal Officer at WIPO AMC Singapore, who shared valuable insights on WIPO’s strategies for handling disputes in IP and technology. • Isha Singh, Legal Case Manager at WIPO AMC Geneva, who wrapped up the event with real-life case studies, highlighting how WIPO ADR has helped life sciences organizations navigate high-stakes conflicts. Thank you to all our members who joined us today and made this event a success! #SAPI #WIPO #IP #Innovation

We are excited to share that Abdullahi Sheriff, Vice President and Chair of SAPI’s Public Policy Committee (PPC), will be speaking at the 2024 APAC Health and Life Sciences Summit on 11 November, touching on how stakeholders in the healthcare industry can partner to drive innovation and ensure health equity and access. The summit will see policymakers, industry leaders, investors and innovators from the health and life sciences industry come together over two days to discuss wide-ranging topics that impact the healthcare industry today, and seek to advance innovation and collaboration in this region. The event promises lively discussions on trends and solutions in the life sciences innovation landscape, the impact of climate change on health and how to build more climate-resilient health systems in Asia. SAPI strongly believes in driving collaborative action to ensure healthcare equity and access for those in Asia, and will continue working towards delivering inclusive solutions that advance patient-centered healthcare for all. Stay tuned for more updates from the session. More information on the speakers can be found here: https://lnkd.in/gwrk3muC #SAPI #HealthEquity #HealthcareAccess #SustainableHealthcare ASK Health Asia

SAPI is honored to have been part of an engaging discussion at the Clinical Research Roundtable 2024 hosted by the Singapore Clinical Research Institute (SCRI)! It was an incredible opportunity to exchange ideas with various experts and leaders in the clinical research ecosystem.   Our President, Hwee Tee Poh, presented on the value proposition of clinical trials, highlighting not only Singapore’s strengths in driving high-quality and innovative research but also the significant benefits clinical trials bring to patients, the healthcare system, clinicians, and the economy.   Our Vice President and Lead of the SAPI Clinical Trial Working Group (CTWG), Yeoh Ying Ying, shared insights on the opportunities and key areas to focus on in order for Singapore to remain competitive in the space of global innovations and clinical trial landscape.   A heartfelt thank you to A/Prof Danny Soon and SCRI for organizing this important event and bringing together key voices in the clinical research community.   Special thanks to the dedicated members of the SAPI CTWG for their tireless efforts in advancing clinical research in Singapore: Atul Chaudhari Michelle Lim, PhD Eric SOONG Cheng Wai Phoon Nicole (Hee Sun) Jun Shireen Lau Pei Yin TAN Olive Chan Lilian Chan Yow Wei T. Luisiawati Khalil-Longbottom Siew Wei Goh Lee Sujung. We look forward to continue collaborating with all stakeholders to drive the outcomes and partnerships sparked by this roundtable, and to further strengthen Singapore’s position as a global leader in clinical trials.   #SAPI #SCRI #ClinicalResearch #ClinicalTrials

We are proud to have our Board Director and Regulatory Affairs Committee Chair, Celine Ting, represent SAPI at CoRE’s 10th Anniversary Scientific Conference! In her presentation on "Effective Collaboration and Partnerships Amongst Stakeholders in the Regulatory Ecosystem – The Pharma Industry Perspective", Celine shared SAPI's experiences from collaborations within the regulatory ecosystem and the valuable lessons we’ve learned to strengthen future partnerships. During the panel discussion "How do we envision the regulatory ecosystem and partnerships by 2030?", Celine emphasised SAPI's ongoing commitment to fostering a more patient-centric approach to healthcare decision-making, highlighting initiatives such as capability-building programs for patient communities and the publication of SAPI's Guidelines for Interactions with Patients, Caregivers and Patient Organisations. Looking ahead, Celine stressed the importance of building sustainable, collaborative relationships with key stakeholders across the ecosystem to support a more resilient and future-ready healthcare environment. A heartfelt thank you to Professor John Lim and Centre of Regulatory Excellence for the invitation and for providing such a meaningful platform. Congratulations on your 10th Anniversary — we look forward to continuing our collaboration to drive excellence in regulatory science and healthcare innovation in the years to come. Hwee Tee Poh Yeoh Ying Ying Abdullahi Sheriff Weeling Quek Christina Teo #SAPI #CoRE10thAnniversary #HealthRegulation

The recent revision of income thresholds to make healthcare more accessible for many Singaporeans is a great step forward. Will there be more positive news to come? As healthcare evolves to address increasingly complex and challenging conditions, how quickly can innovative treatments and vaccines be integrated into subsidy frameworks to benefit more patients? Timely access to cutting-edge treatments is especially critical for those living with rare or complex conditions. It’s not just about affordability today—but creating a healthcare system that meets the needs of tomorrow. Striking a balance between immediate affordability, sustainable funding and sustained access to innovation is more important than ever. At SAPI, we believe that continuous collaboration across the healthcare ecosystem— bringing together patients, researchers, manufacturers, payers and providers—is essential to delivering inclusive, long-lasting solutions that advance patient-centred healthcare for all.

SAPI welcomes Prime Minister Lawrence Wong's recent remarks at the National Day Rally, which underscore the importance of innovation, productivity, and a business-friendly environment in driving Singapore’s next phase of economic growth. As an integral part of Singapore's healthcare and R&D ecosystem, our industry remains dedicated to supporting these national priorities and driving initiatives that enhance Singapore’s progress and well-being. Read more about our continued commitments to support efforts to achieve these goals. #SAPI #NDR2024 #StrongerTogether #SustainableHealthcare #HealthcareInnovation 

As we wrap up Q2, SAPI members have been keeping busy with various announcements. #SAPICelebrates their remarkable milestones and significant contributions of our members to healthcare and beyond. Key highlights include: ·       The opening of Pfizer’s new pharmaceutical ingredient plant in Tuas Biomedical Park, which will produce active pharmaceutical ingredients for cancer, pain and antibiotic medicines, and AstraZeneca’s and Novartis Singapore’ plans and announcements on their respective manufacturing facilities, have reinforced Singapore’s standing as a leading biomedical sciences hub. ·       Roche announced a partnership with the Singapore Translational Cancer Consortium to join the Roche-led imCORE Network, a global initiative to accelerate research and development of cancer immunotherapy treatments.   ·       DKSH and Kyowa Kirin Co., Ltd. announced a partnership to enhance patient accessibility to life-changing treatments in Singapore and the region. ·       Amgen, AstraZeneca and Changi Airport Group were conferred the top honour of Champions of Good 2024 by Company of Good, as they push the boundaries to deliver medicines to patients and for their commitment to making a positive impact on the world. ·       Johnson & Johnson, Kyowa Kirin Co., Ltd. and Menarini Asia-Pacific were also recognised as Companies of Good. Congratulations to our SAPI members for their unwavering commitment to improving lives and driving positive change! Yeoh Ying Ying, Suyeon Kim, Reuben Ong, Serene Chang, Marcus Desmond, Hwee Tee Poh, Deborah Seifert, Amelia Mok, Boon Heon Tan, PhD, Jaisey Yip #SAPICelebrates #SAPI #Pfizer #Novartis #Roche #DKSH #KyowaKirin #Amgen #AstraZeneca #ChangiAirportGroup #JNJ #Menarini

SAPI President Hwee Tee Poh and Vice President Yeoh Ying Ying recently participated in two panels as part of the Singapore Clinical Research Institute (SCRI) Clinical Trials Symposium, an event that brought professionals in clinical research around the world together, to showcase the value proposition of clinical trials in Singapore. In the first day’s plenary session, Hwee Tee, alongside other esteemed panellists such as Prof Kenneth Mak, Adj A/Prof Danny Soon, Mr Adrian Yap, A/Prof David SP Tan and Dr Daph Gardner, explored the value of clinical trials from the patient, healthcare professionals and industry perspectives, covering topics on access to new treatments, evidence-based practice and innovation. On the second day, Ying Ying moderated a panel including Prof C. Michael Gibson, M.S., M.D., Ms Mingshi Koh and Prof Khung Keong Yeo to discuss innovations in data-driven research, and how data can unlock different possibilities for research and its impact on patients. Thank you to all panellists and SCRI for the engaging and enriching event! Through important dialogue sessions such as this and collaborative efforts, we can further strengthen Singapore's position as a leading clinical trial hub. SAPI is committed to working with all stakeholders to streamline processes, enhance support systems, and foster innovation, ensuring patients receive early access to cutting-edge treatments. We deeply value SCRI's longstanding partnership and look forward to our continued collaboration in this vital mission. Learn more about Hwee Tee and Ying Ying’s key takeaways from the sessions in the slides below. 📷 Consortium for Clinical Research and Innovation, Singapore (CRIS) #SCRIClinicalTrialsSymposium2024 #SAPI #ClinicalTrials #ClinicalResearch